Palo Alto Investors LP reported a buy of 41,303 shares of PTC Therapeutics (NASDAQ:PTCT) in its February 17, 2026, SEC filing, with an estimated transaction value of $3.00 million based on quarterly average pricing.
Palo Alto Investors LP reported a buy of 41,303 shares of PTC Therapeutics (NASDAQ:PTCT) in its February 17, 2026, SEC filing, with an estimated transaction value of $3.00 million based on quarterly average pricing.